Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-DA-EDOCH alternating with R-DHAP in younger Mantle Cell Lymphoma
NCT02858804Phase 4Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2016
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab in mantle cell lymphoma (MCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jan 2016; status: completed.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02858804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858804.